FDA Takes Action To Restrict Unlawful Import Of Animal Tranquilizer ‘Tranq’ Or ”Zombie Drug’
The FDA issued an “import alert” about the animal tranquilizer xylazine, also called “tranq,” “tranq dope,” and “zombie drug.” The…
12 Health Care Stocks Moving In Monday’s Intraday Session
Gainers Cardio Diagnostics Hldgs (NASDAQ:CDIO) stock rose 92.8% to $2.28 during Monday’s regular session. Cardio Diagnostics Hldgs’s stock…
Stocks That Hit 52-Week Lows On Friday
During Friday's trading, 293 companies set new 52-week lows.
Xenetic Biosciences Cash Position $14.9M
Xenetic Biosciences (NASDAQ:XBIO) will report on Q2 2022.
Xenetic Biosciences Enters Exclusive License And Sublicense Agreements With CLS Therapeutics; Xenetic To Make Upfront Payment Of $500K In Cash And Issue 875K Shares Of Common Stock As Well As Up To $13M In Future Milestones
Transaction with CLS Therapeutics for DNase platform includes two pre-clinical development programs and creates near-term clinical development opportunity
DNase based oncology platform has the potential to improve
‘We are expanding the potential of CAR T cell therapy through the development of our XCART technology platform…’ -Tweet From Xenetic Biosciences
https://twitter.com/XeneticBio/status/1468617160029347846
